| Potential Counseling & Consultation Services Llc | |
|
2800 Orchard Dr Ste B Cedar Falls IA 50613-5898 | |
| (319) 464-2389 | |
| (866) 375-8530 |
| Full Name | Potential Counseling & Consultation Services Llc |
|---|---|
| Speciality | Counselor |
| Location | 2800 Orchard Dr Ste B, Cedar Falls, Iowa |
| Authorized Official Name and Position | Jennifer Brost (OWNER, THERAPIST) |
| Authorized Official Contact | 3194642389 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Potential Counseling & Consultation Services Llc 320 Drynan Dr Waterloo IA 50701-1622 Ph: (319) 464-2389 | Potential Counseling & Consultation Services Llc 2800 Orchard Dr Ste B Cedar Falls IA 50613-5898 Ph: (319) 464-2389 |
| NPI Number | 1972119402 |
|---|---|
| Provider Enumeration Date | 09/21/2020 |
| Last Update Date | 02/20/2024 |
| Certification Date | 02/20/2024 |
| Medicare PECOS PAC ID | 8628413929 |
|---|---|
| Medicare Enrollment ID | O20240227000248 |
News Archive
AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced the pricing of its initial public offering of 8 million shares of common stock at $5.00 per share. All of the common stock will be sold by AcelRx.
In a paper published in the September/December 2018 issue of TECHNOLOGY, a group of researchers from Rutgers University Department of Biomedicine Engineering have published a review paper on the transformative potential of precision and personalized medicine (PPM) for cancer treatment.
"Hepatitis B virus infection causes infant fulminant hepatitis, and chronic HBV infection may progress to chronic liver disease and hepatocellular carcinoma. Taiwan launched a nationwide HBV immunization program for newborns in July 1984, which has successfully lowered the prevalence of chronic HBV carriers, incidence of HCC, and mortality of IFH in vaccinated birth cohorts. The mortality of CLD before and after HBV immunization has never been examined," write Chun-Ju Chiang, Ph.D., of National Taiwan University, Taipei, and colleagues.
Lotus Pharmaceuticals, Inc. a growing developer and producer of prescriptions drugs and licensed national seller of pharmaceutical products in the People's Republic of China, today reported third-quarter 2009 net earnings were $5.4 million, or $0.11 per diluted share, compared with $3.2 million, or $0.07 per diluted share, in 2008. Net revenues were $14.5 million during the third quarter of 2009, compared with $16.7 million in the third quarter of 2008.
› Verified 4 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1972119402 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 101YM0800X | Counselor - Mental Health | (* (Not Available)) | Primary |
| Provider Name | Jennifer Lynn Brost |
|---|---|
| Provider Type | Practitioner - Mental Health Counselor |
| Provider Identifiers | NPI Number: 1821346099 PECOS PAC ID: 9537504832 Enrollment ID: I20240227000304 |
News Archive
AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced the pricing of its initial public offering of 8 million shares of common stock at $5.00 per share. All of the common stock will be sold by AcelRx.
In a paper published in the September/December 2018 issue of TECHNOLOGY, a group of researchers from Rutgers University Department of Biomedicine Engineering have published a review paper on the transformative potential of precision and personalized medicine (PPM) for cancer treatment.
"Hepatitis B virus infection causes infant fulminant hepatitis, and chronic HBV infection may progress to chronic liver disease and hepatocellular carcinoma. Taiwan launched a nationwide HBV immunization program for newborns in July 1984, which has successfully lowered the prevalence of chronic HBV carriers, incidence of HCC, and mortality of IFH in vaccinated birth cohorts. The mortality of CLD before and after HBV immunization has never been examined," write Chun-Ju Chiang, Ph.D., of National Taiwan University, Taipei, and colleagues.
Lotus Pharmaceuticals, Inc. a growing developer and producer of prescriptions drugs and licensed national seller of pharmaceutical products in the People's Republic of China, today reported third-quarter 2009 net earnings were $5.4 million, or $0.11 per diluted share, compared with $3.2 million, or $0.07 per diluted share, in 2008. Net revenues were $14.5 million during the third quarter of 2009, compared with $16.7 million in the third quarter of 2008.
› Verified 4 days ago
News Archive
AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced the pricing of its initial public offering of 8 million shares of common stock at $5.00 per share. All of the common stock will be sold by AcelRx.
In a paper published in the September/December 2018 issue of TECHNOLOGY, a group of researchers from Rutgers University Department of Biomedicine Engineering have published a review paper on the transformative potential of precision and personalized medicine (PPM) for cancer treatment.
"Hepatitis B virus infection causes infant fulminant hepatitis, and chronic HBV infection may progress to chronic liver disease and hepatocellular carcinoma. Taiwan launched a nationwide HBV immunization program for newborns in July 1984, which has successfully lowered the prevalence of chronic HBV carriers, incidence of HCC, and mortality of IFH in vaccinated birth cohorts. The mortality of CLD before and after HBV immunization has never been examined," write Chun-Ju Chiang, Ph.D., of National Taiwan University, Taipei, and colleagues.
Lotus Pharmaceuticals, Inc. a growing developer and producer of prescriptions drugs and licensed national seller of pharmaceutical products in the People's Republic of China, today reported third-quarter 2009 net earnings were $5.4 million, or $0.11 per diluted share, compared with $3.2 million, or $0.07 per diluted share, in 2008. Net revenues were $14.5 million during the third quarter of 2009, compared with $16.7 million in the third quarter of 2008.
› Verified 4 days ago
Katie Rogers Counseling Pllc Mental Health Clinic Medicare: Medicare Enrolled Practice Location: 215 Franklin St, Cedar Falls, IA 50613 Phone: 319-214-5626 | |
Rachael Jorgensen, Pllc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 215 Franklin St, Cedar Falls, IA 50613 Phone: 319-415-6405 | |
Robert Boezinger, Pllc Mental Health Clinic Medicare: Medicare Enrolled Practice Location: 215 Franklin Street, Cedar Falls, IA 50613 Phone: 563-340-6545 | |
Extension Of Grace Mental Health Clinic Medicare: Medicare Enrolled Practice Location: 4615 Chadwick Rd, Cedar Falls, IA 50613 Phone: 319-255-5660 Fax: 319-237-7639 | |
Life Steps Therapy Solutions, Pllc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 4730 Loren Dr, Cedar Falls, IA 50613 Phone: 309-507-1768 | |
Mindfulife, Llc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 2302 W 1st St Ste 126, Cedar Falls, IA 50613 Phone: 319-448-3156 Fax: 319-205-1368 | |
Fts Counseling Pllc Mental Health Clinic Medicare: Medicare Enrolled Practice Location: 215 Franklin St, Cedar Falls, IA 50613 Phone: 913-912-0334 |